Development of PLGA (Poly Lactic-co-glycolic acid) nanoparticles polymer is intended to achieve controlled release at specific places in the body. Stability of nanoparticles can be enhanced by stabilizer agents such as PVA (Polyvinyl Alcohol) by preventing agglomeration. In this study, dexamethasone sodium phospate formulated in the form of nanoparticles. This study aims to determine the effect of the amount of PVA (Polyvinyl Alcohol) in PLGA (Poly Lactic-co-Glycolic Acid) nanoparticles. Preparation is done by solvent evaporation.Nanoparticle formulations made with variation of PVA 25 mg, 62.5 mg and 125 mg. Characterization of nanoparticles include organoleptic, determination globule size, zeta potential measurement, morphology testing, and measurement of the determination encapsulation efficiency (% EE). In formula PVA 25 mg resulted a particle size of 799,6 nm, polydispersity index 0,256, zeta potential -5 mV, and encapsulation efficiency 27,9%. In formula PVA 62,5 mg resulted a particle size of 465,7 nm, polydispersity index 0,006, zeta potential -4,5 mV, and efficiency encapsulation 34,67%. In formula PVA 125 mg resulted a particle size of 468,9 nm, polydispersity index 0,228, zeta potential -4,3 mV, and efficiency encapsulation 14,85%. The addition of PVA can improve the stability of nanoparticles. 
Keywords: Nanoparticle, PLGA, PVA, dexamethasone sodium phospate.